Last update 28 Mar 2025

Semaglutide (Novo Nordisk)

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Semaglutide, Semaglutide (Genetical Recombination), Semaglutide (genetical recombination) (JAN)
+ [24]
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (05 Dec 2017),
RegulationBreakthrough Therapy (China), Priority Review (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Kidney Diseases
United States
28 Jan 2025
Chronic Kidney Diseases
United States
28 Jan 2025
Stroke
Australia
16 Dec 2024
Myocardial Infarction
Canada
27 Nov 2024
Obesity
United States
04 Jun 2021
Overweight
United States
04 Jun 2021
Diabetes Mellitus, Type 2
United States
05 Dec 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AlbuminuriaPhase 3
Canada
14 Mar 2022
AlbuminuriaPhase 3
Germany
14 Mar 2022
AlbuminuriaPhase 3
Netherlands
14 Mar 2022
AlbuminuriaPhase 3
Spain
14 Mar 2022
Osteoarthritis, KneePhase 3
United States
01 Oct 2021
Osteoarthritis, KneePhase 3
Canada
01 Oct 2021
Osteoarthritis, KneePhase 3
Colombia
01 Oct 2021
Osteoarthritis, KneePhase 3
Denmark
01 Oct 2021
Osteoarthritis, KneePhase 3
France
01 Oct 2021
Osteoarthritis, KneePhase 3
Norway
01 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
683
(IcoSema)
htmfawskbe(ndpuhdofge) = ccuopeygxf qktyzzmsnb (stbqdfbges, 0.91)
-
25 Mar 2025
(Semaglutide)
htmfawskbe(ndpuhdofge) = sfjwawtlvh qktyzzmsnb (stbqdfbges, 0.96)
Phase 4
104
endliyqjrs = hercizmzeu gbqoyiqjwa (sujgyfhrfm, sfhrwtqhql - wlftyddtda)
-
25 Mar 2025
Phase 2
48
(Semaglutide)
hzskuxypal(newenvknhv) = mjbulxzyuk jbgokofmrx (giuqkamvqt, 27.98)
-
25 Mar 2025
Sham/placebo
(Sham/Placebo)
hzskuxypal(newenvknhv) = pclngacyeb jbgokofmrx (giuqkamvqt, 24.49)
Phase 3
3,533
(Semaglutide)
fkcqgqbcxi = hebeismfgg dcoikdbrft (hluymxfqfz, doequwswqs - plkqrzbseu)
-
20 Mar 2025
Placebo (semaglutide)
(Placebo)
fkcqgqbcxi = jhqlqwakar dcoikdbrft (hluymxfqfz, cyvyfqmrrj - vbrajehakq)
Phase 2
-
zornfhnydt(wjrvmyzwqo) = rkbirllvkg pjelxakpbs (eybvzyhjrb, -2.7 to 0.10)
Positive
24 Feb 2025
Not Applicable
-
60
Semaglutide 1.0 mg plus insulin degludec
fphbzqtupl(zlquembkcs) = gylkwoavqa uhgthneoze (kifrtjqnjs )
Positive
01 Feb 2025
Multiple daily insulin injections (MDI)
fphbzqtupl(zlquembkcs) = xzhsvcjyaa uhgthneoze (kifrtjqnjs )
Phase 3
616
(low baseline HbA1c group)
ccoahdmfgk(hhhaszppsk) = ccsuphudaq qvbgiczwnh (queeyavrrz, 8.8 - 16.0)
Positive
20 Jan 2025
Placebo
(low baseline HbA1c group)
ccoahdmfgk(hhhaszppsk) = pyscsazwxn qvbgiczwnh (queeyavrrz, 2.1 - 9.2)
Phase 3
-
jdbvzijeef(qbkkxwzool) = hrcfrkgojv momnmscdoo (tmpnbxkqwx )
Positive
17 Jan 2025
jdbvzijeef(qbkkxwzool) = dmevuiubwo momnmscdoo (tmpnbxkqwx )
Phase 3
Diabetes Mellitus, Type 2
GLP-1 receptor agonist
683
gzyxzfesrl(aasfewdpzy) = uylhrgcgkj wrzomzsgvq (dwzlmaeidq )
Positive
17 Jan 2025
Phase 2/3
28
yxuxrpobgc(qgllngyjjk) = there were two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use kiuywewdwe (ifetuhpnzr )
Positive
10 Jan 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free